Alloy has launched an expansion to its M4 collection, introducing M4 Body Treatment Rx, a prescription-strength topical designed specifically for menopausal skin. The new product combines bioidentical estriol with peptides to address body skin concerns common during menopause, including dryness, loss of elasticity, and thinning skin.
The M4 line, which already established itself in the menopausal skincare market, moves beyond facial products with this body treatment. Estriol, a form of estrogen, works to restore skin thickness and hydration at the cellular level. The addition of peptides supports collagen production and skin firmness, targeting the widespread texture and moisture loss that many women experience during hormonal shifts.
This product positions itself as a clinical solution rather than a cosmetic one, requiring a prescription. That distinction matters. Prescription-grade skincare occupies a different regulatory space than over-the-counter products, allowing for higher concentrations of active ingredients and different claims.
The menopausal skincare market has expanded significantly in recent years as brands recognize this demographic's specific needs. Products targeting hormonal changes have moved from niche to mainstream, with companies understanding that menopause involves skin changes that differ from typical aging. Body skin, often neglected in anti-aging routines, faces particular challenges during this transition. Skin on the neck, chest, hands, and torso tends to thin faster and show dehydration more visibly than facial skin.
Alloy's M4 Body Treatment Rx addresses a gap in the menopausal skincare category. While facial serums and creams targeting estriol and hormonal support have proliferated, dedicated body treatments remain limited. The prescription model also suggests clinical backing and efficacy standards that differ from over-the-counter alternatives.
For consumers navigating menopausal